During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ...

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

After a bidding war erupted between Pfizer and Novo Nordisk over the fledgling obesity drug maker, Metsera decided to side with its original suitor.

The Phase III results impressed Guggenheim Partners analysts both in terms of efficacy and safety. If approved, atacicept would become the first APRIL/BAFF inhibitor for IgAN to make it to the market.